PT - JOURNAL ARTICLE AU - Formica, Neil AU - Mallory, Raburn AU - Albert, Gary AU - Robinson, Michelle AU - Plested, Joyce S. AU - Cho, Iksung AU - Robertson, Andreana AU - Dubovsky, Filip AU - Glenn, Gregory M. AU - , TI - Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373 in Younger and Older Adults AID - 10.1101/2021.02.26.21252482 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.26.21252482 4099 - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252482.short 4100 - http://medrxiv.org/content/early/2021/03/01/2021.02.26.21252482.full AB - Background NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant.Methods The phase 2 component of our randomized, placebo-controlled, phase 1-2 trial was designed to identify which dosing regimen of NVX-CoV2373 should move forward into late phase studies in younger (18-59 years) and older (60-84 years) participants and was based on immunogenicity and safety data through day 35 (14 days after the second dose). Participants were randomly assigned to receive either one or two intramuscular doses of 5-µg or 25-µg NVX-CoV2373 or placebo, 21 days apart. Primary endpoints were immunoglobulin G (IgG) anti-spike protein response, 7-day solicited reactogenicity, and unsolicited adverse events. A key secondary endpoint was wild-type virus neutralizing antibody response.Results After randomization, approximately 250 participants each were assigned to one of four vaccine groups or placebo. Of these, approximately 45% were older participants. Reactogenicity was predominantly mild to moderate in severity and of short duration (median <3 days) after first and second vaccination with NVX-CoV2373, with higher frequencies and intensity after second vaccination and with the higher dose, and occurred less frequently and was of lower intensity in older participants. The two-dose regimen of 5-µg NVX-CoV2373 induced robust geometric mean titer (GMT) IgG anti-spike protein (65,019 and 28,137 EU/mL) and wild-type virus neutralizing antibody (2201 and 981 titers) responses in younger and older participants, respectively, with seroconversion rates of 100% in both age groups. Neutralizing antibody responses exceeded those seen in convalescent sera for both age groups.Conclusions The study confirmed that the two-dose regimen of 5-µg NVX-CoV2373 is highly immunogenic and well tolerated in both younger and older participants.(Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number: NCT04368988).Competing Interest StatementAll authors are employees of Novavax, Inc. or were at the time of the studyClinical TrialNCT04368988Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04368988?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=4 Funding StatementThe trial was designed by Novavax, Inc. (Gaithersburg, Maryland, USA), with funding support from the Coalition for Epidemic Preparedness InnovationsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the Alfred Hospital Human Research Ethics Committee (Melbourne, Australia) and Advarra Central Institutional Review Board (Colombia, Maryland, USA) and was performed in accordance with the International Conference on Harmonisation, Good Clinical Practice guidelines. Safety oversight for the older adult lead-in enrollment cohort and specific vaccination pause rules were supported by an independent safety monitoring committeeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese are interim data, and individual participants remain masked to individual vaccine assignment. Therefore, it would be inappropriate to share individual level results at this time. https://clinicaltrials.gov/ct2/show/NCT04368988?term=NVX-CoV2373+Covid-19+Vaccine&draw=2&rank=4